News coverage about Aradigm (NASDAQ:ARDM) has been trending somewhat positive recently, according to Accern. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aradigm earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.0562207100708 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Aradigm (NASDAQ ARDM) traded up $0.03 on Tuesday, hitting $4.30. The stock had a trading volume of 188,400 shares, compared to its average volume of 160,299. Aradigm has a one year low of $0.78 and a one year high of $5.68. The company has a debt-to-equity ratio of -1.59, a quick ratio of 1.65 and a current ratio of 1.65.
Aradigm (NASDAQ:ARDM) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.26) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.05. The company had revenue of $2.73 million for the quarter. Aradigm had a negative return on equity of 665.03% and a negative net margin of 118.37%. equities research analysts expect that Aradigm will post -0.74 earnings per share for the current year.
A number of equities analysts have recently weighed in on the company. Zacks Investment Research lowered Aradigm from a “buy” rating to a “hold” rating in a research note on Thursday, August 24th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $10.00 target price (up previously from $7.50) on shares of Aradigm in a research note on Monday, September 25th.
TRADEMARK VIOLATION NOTICE: “Aradigm (ARDM) Receiving Somewhat Favorable Media Coverage, Report Finds” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/05/aradigm-ardm-receiving-somewhat-favorable-media-coverage-report-finds-2.html.
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.
Receive News & Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.